Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 3.50
GNMK's Cash-to-Debt is ranked higher than
55% of the 288 Companies
in the Global Medical Devices industry.

( Industry Median: 2.45 vs. GNMK: 3.50 )
Ranked among companies with meaningful Cash-to-Debt only.
GNMK' s Cash-to-Debt Range Over the Past 10 Years
Min: 3.5  Med: 2853.76 Max: No Debt
Current: 3.5
Equity-to-Asset 0.48
GNMK's Equity-to-Asset is ranked lower than
66% of the 265 Companies
in the Global Medical Devices industry.

( Industry Median: 0.62 vs. GNMK: 0.48 )
Ranked among companies with meaningful Equity-to-Asset only.
GNMK' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.48  Med: 0.8 Max: 0.9
Current: 0.48
0.48
0.9
Piotroski F-Score: 2
Altman Z-Score: 1.32
Beneish M-Score: -3.22
WACC vs ROIC
8.99%
-441.65%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -99.41
GNMK's Operating Margin % is ranked lower than
79% of the 270 Companies
in the Global Medical Devices industry.

( Industry Median: 2.62 vs. GNMK: -99.41 )
Ranked among companies with meaningful Operating Margin % only.
GNMK' s Operating Margin % Range Over the Past 10 Years
Min: -4488.56  Med: -127.65 Max: -99.41
Current: -99.41
-4488.56
-99.41
Net Margin % -102.69
GNMK's Net Margin % is ranked lower than
78% of the 270 Companies
in the Global Medical Devices industry.

( Industry Median: 1.50 vs. GNMK: -102.69 )
Ranked among companies with meaningful Net Margin % only.
GNMK' s Net Margin % Range Over the Past 10 Years
Min: -4383.77  Med: -125.07 Max: -102.69
Current: -102.69
-4383.77
-102.69
ROE % -125.54
GNMK's ROE % is ranked lower than
89% of the 263 Companies
in the Global Medical Devices industry.

( Industry Median: 2.08 vs. GNMK: -125.54 )
Ranked among companies with meaningful ROE % only.
GNMK' s ROE % Range Over the Past 10 Years
Min: -285.43  Med: -92.73 Max: -40.63
Current: -125.54
-285.43
-40.63
ROA % -70.13
GNMK's ROA % is ranked lower than
81% of the 291 Companies
in the Global Medical Devices industry.

( Industry Median: 0.20 vs. GNMK: -70.13 )
Ranked among companies with meaningful ROA % only.
GNMK' s ROA % Range Over the Past 10 Years
Min: -186.91  Med: -67.03 Max: -35.46
Current: -70.13
-186.91
-35.46
ROC (Joel Greenblatt) % -343.10
GNMK's ROC (Joel Greenblatt) % is ranked lower than
77% of the 288 Companies
in the Global Medical Devices industry.

( Industry Median: 4.02 vs. GNMK: -343.10 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
GNMK' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1238.95  Med: -441.27 Max: -330.13
Current: -343.1
-1238.95
-330.13
3-Year Revenue Growth Rate 12.90
GNMK's 3-Year Revenue Growth Rate is ranked higher than
75% of the 227 Companies
in the Global Medical Devices industry.

( Industry Median: 4.60 vs. GNMK: 12.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
GNMK' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -22.2  Med: 23.85 Max: 52.5
Current: 12.9
-22.2
52.5
3-Year EBITDA Growth Rate 5.10
GNMK's 3-Year EBITDA Growth Rate is ranked higher than
50% of the 199 Companies
in the Global Medical Devices industry.

( Industry Median: 5.60 vs. GNMK: 5.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
GNMK' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -63.4  Med: -17.15 Max: 5.1
Current: 5.1
-63.4
5.1
3-Year EPS without NRI Growth Rate 6.60
GNMK's 3-Year EPS without NRI Growth Rate is ranked higher than
55% of the 197 Companies
in the Global Medical Devices industry.

( Industry Median: 3.40 vs. GNMK: 6.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
GNMK' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -62.8  Med: -17.05 Max: 6.6
Current: 6.6
-62.8
6.6
GuruFocus has detected 6 Warning Signs with GenMark Diagnostics Inc $GNMK.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» GNMK's 10-Y Financials

Financials (Next Earnings Date: 2017-04-10 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

GNMK Guru Trades in Q1 2016

Jim Simons 71,300 sh (New)
» More
Q2 2016

GNMK Guru Trades in Q2 2016

Jim Simons Sold Out
» More
Q3 2016

GNMK Guru Trades in Q3 2016

Jim Simons 109,000 sh (New)
» More
Q4 2016

GNMK Guru Trades in Q4 2016

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with GNMK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339113    SIC: 3841
Compare:OTCPK:SBMAF, OTCPK:MZRTF, NYSE:CRY, NAS:OFIX, OTCPK:NMRD, NAS:XENT, NAS:VRAY, NAS:KTWO, NAS:ARAY, NAS:EXAC, NAS:ELOS, NYSE:IVC, NAS:CSII, NAS:AXGN, NAS:TCMD, NAS:CUTR, NAS:VASC, NAS:MDXG, NAS:HTWR, AMEX:CVRS » details
Traded in other countries:GNF.Germany,
GenMark Diagnostics Inc is a molecular diagnostics company. The Company develops and commercializes its proprietary eSensor detection technology for the support of instruments and molecular tests.

GenMark Diagnostics Inc was incorporated in the State of Delaware in February 2010. The Company is a molecular diagnostics company developing and commercializing its proprietary eSensor detection technology. Its proprietary electrochemical technology enables fast, accurate and sensitive detection of up to 72 distinct biomarkers in a single sample. The Company's XT-8 System received 510(k) clearance from the Food and Drug Administration and is designed to support molecular diagnostic tests with a compact and easy-to-use workstation and self-contained, disposable test cartridges. Within 30 minutes of receipt of an amplified nucleic acid sample, its XT-8 system produces clear results. The Company's XT-8 System supports up to 24 test cartridges, of which each could be run independently, resulting in a convenient and flexible workflow for its customers, which are hospitals and reference laboratories. It intends to expand the use of its XT-8 System and diagnostic tests to those reference laboratories and hospitals in the United States which perform a high volume of molecular diagnostic tests. The Company's XT-8 System is an automated molecular diagnostic system that enables reference laboratories and hospitals to perform fast, accurate and easy-to-use molecular diagnostic tests. The XT-8 System, which employs its proprietary electrochemical detection technology, consists of a compact bench-top workstation with an integrated touch screen computer and an analyzer into which the self-contained, disposable test cartridges are inserted. The Company's proprietary eSensor technology is based on the competitive DNA hybridization and electrochemical detection. The Company's test cartridges are self-contained devices specifically programmed and configured for a given diagnostic test. Each test cartridge includes a sample compartment and a plastic cover that forms a hybridization chamber. The Company's XT-8 instrument is a multiplex workstation that has a modular design consisting of a base module and up to three test cartridge-processing towers of eight cartridge slots each. It faces competition in the molecular diagnostic testing markets with testing products and systems developed by public and private companies such as Cepheid, Gen-Probe, Inc., Siemens, Hologic, Inc., Innogenetics, Inc, Luminex Corporation, Nanosphere, Inc., Qiagen NV, Roche Diagnostics, a division of F. Hoffmann-La Roche Ltd., Idaho Technologies and Abbott Diagnostics, a division of Abbott Laboratories. The Company's diagnostic tests also face competition with the LDTs developed by national and regional reference laboratories and hospitals. The design, development, manufacture, testing and sale of its diagnostic products are subject to regulation by numerous governmental authorities, the FDA, and corresponding state and foreign regulatory agencies.

Ratios

vs
industry
vs
history
PB Ratio 16.08
GNMK's PB Ratio is ranked lower than
95% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 3.35 vs. GNMK: 16.08 )
Ranked among companies with meaningful PB Ratio only.
GNMK' s PB Ratio Range Over the Past 10 Years
Min: 1.61  Med: 4.96 Max: 16.18
Current: 16.08
1.61
16.18
PS Ratio 11.62
GNMK's PS Ratio is ranked lower than
84% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 3.31 vs. GNMK: 11.62 )
Ranked among companies with meaningful PS Ratio only.
GNMK' s PS Ratio Range Over the Past 10 Years
Min: 4.96  Med: 13.61 Max: 23.37
Current: 11.62
4.96
23.37
Current Ratio 2.21
GNMK's Current Ratio is ranked lower than
52% of the 284 Companies
in the Global Medical Devices industry.

( Industry Median: 2.33 vs. GNMK: 2.21 )
Ranked among companies with meaningful Current Ratio only.
GNMK' s Current Ratio Range Over the Past 10 Years
Min: 2.21  Med: 5.53 Max: 10.85
Current: 2.21
2.21
10.85
Quick Ratio 1.96
GNMK's Quick Ratio is ranked higher than
56% of the 284 Companies
in the Global Medical Devices industry.

( Industry Median: 1.67 vs. GNMK: 1.96 )
Ranked among companies with meaningful Quick Ratio only.
GNMK' s Quick Ratio Range Over the Past 10 Years
Min: 1.96  Med: 5.49 Max: 10.65
Current: 1.96
1.96
10.65
Days Inventory 70.25
GNMK's Days Inventory is ranked higher than
80% of the 254 Companies
in the Global Medical Devices industry.

( Industry Median: 125.58 vs. GNMK: 70.25 )
Ranked among companies with meaningful Days Inventory only.
GNMK' s Days Inventory Range Over the Past 10 Years
Min: 47.43  Med: 65.24 Max: 182.73
Current: 70.25
47.43
182.73
Days Sales Outstanding 67.02
GNMK's Days Sales Outstanding is ranked higher than
50% of the 240 Companies
in the Global Medical Devices industry.

( Industry Median: 66.89 vs. GNMK: 67.02 )
Ranked among companies with meaningful Days Sales Outstanding only.
GNMK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 38.08  Med: 63.41 Max: 96.52
Current: 67.02
38.08
96.52
Days Payable 161.25
GNMK's Days Payable is ranked higher than
84% of the 227 Companies
in the Global Medical Devices industry.

( Industry Median: 57.49 vs. GNMK: 161.25 )
Ranked among companies with meaningful Days Payable only.
GNMK' s Days Payable Range Over the Past 10 Years
Min: 70.64  Med: 104.28 Max: 266.25
Current: 161.25
70.64
266.25

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -3.90
GNMK's 3-Year Average Share Buyback Ratio is ranked lower than
53% of the 209 Companies
in the Global Medical Devices industry.

( Industry Median: -3.40 vs. GNMK: -3.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
GNMK' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -172.9  Med: -39.65 Max: -3.9
Current: -3.9
-172.9
-3.9

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 38.29
GNMK's Price-to-Net-Current-Asset-Value is ranked lower than
91% of the 217 Companies
in the Global Medical Devices industry.

( Industry Median: 6.50 vs. GNMK: 38.29 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
GNMK' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.64  Med: 6.34 Max: 38.51
Current: 38.29
2.64
38.51
Price-to-Tangible-Book 17.63
GNMK's Price-to-Tangible-Book is ranked lower than
87% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 4.19 vs. GNMK: 17.63 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
GNMK' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.28  Med: 5.4 Max: 17.74
Current: 17.63
2.28
17.74
Price-to-Median-PS-Value 0.87
GNMK's Price-to-Median-PS-Value is ranked higher than
70% of the 258 Companies
in the Global Medical Devices industry.

( Industry Median: 1.07 vs. GNMK: 0.87 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
GNMK' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.61  Med: 0.96 Max: 1.35
Current: 0.87
0.61
1.35
Earnings Yield (Greenblatt) % -8.30
GNMK's Earnings Yield (Greenblatt) % is ranked lower than
64% of the 339 Companies
in the Global Medical Devices industry.

( Industry Median: -0.81 vs. GNMK: -8.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
GNMK' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -730.68  Med: 0 Max: 0
Current: -8.3
-730.68
0

More Statistics

Revenue (TTM) (Mil) $49.27
EPS (TTM) $ -1.14
Beta0.84
Short Percentage of Float12.86%
52-Week Range $4.66 - 13.43
Shares Outstanding (Mil)47.05

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 65 91
EPS ($) -0.98 -0.77
EPS without NRI ($) -0.98 -0.77
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for GNMK

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: Twitter, GenMark Diagnostics, FireEye Nov 09 2015 
Weekly CFO Buys Highlight: SunEdison Inc, Genpact Ltd, GenMark Diagnostics Inc. Aug 31 2015 
Weekly CFO Buys Highlight: XPL, GNMK Jul 02 2012 
Weekly CEO Buys Highlight: SXL, JBSS, GNMK, CNDO, DCO Jun 30 2012 
Weekly CFO Buys Highlight: Bank Mutual Corp., Heelys Inc., GenMark Diagnostics Inc., Regeneration Te Sep 19 2010 
Weekly CFO Buys Highlight: GNMK, RTIX, BKOR, PTEK, CLDX Sep 12 2010 

More From Other Websites
GenMark Diagnostics, Inc. :GNMK-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017 Mar 07 2017
GENMARK DIAGNOSTICS, INC. Financials Mar 04 2017
GenMark Diagnostics to Present at Cowen and Company’s 37th Annual Health Care Conference Mar 02 2017
GENMARK DIAGNOSTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition Feb 28 2017
GENMARK DIAGNOSTICS, INC. Files SEC form 10-K, Annual Report Feb 28 2017
GenMark Diagnostics reports 4Q loss Feb 28 2017
GenMark Diagnostics reports 4Q loss Feb 28 2017
4:12 pm GenMark Diagnostics reports EPS in-line, revs in-line; guides FY17 revs in-line Feb 28 2017
GenMark Diagnostics Reports Fourth Quarter and Full Year 2016 Results Feb 28 2017
Q4 2016 GenMark Diagnostics Inc Earnings Release - After Market Close Feb 28 2017
GENMARK DIAGNOSTICS, INC. Files SEC form 8-K, Financial Statements and Exhibits Feb 24 2017
GenMark Diagnostics Schedules Fourth Quarter 2016 Financial Results Conference Call for February 28,... Feb 09 2017
GenMark Diagnostics, Inc. breached its 50 day moving average in a Bearish Manner : GNMK-US : January... Jan 31 2017
7 Stocks Making Big Moves With Unusual Volume Jan 11 2017
GenMark Diagnostics, Inc. – Value Analysis (NASDAQ:GNMK) : January 10, 2017 Jan 10 2017
GENMARK DIAGNOSTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Jan 10 2017
GenMark Announces Preliminary Q4 2016 Financial Results Jan 10 2017
GenMark Diagnostics, Inc. breached its 50 day moving average in a Bearish Manner : GNMK-US : January... Jan 09 2017
GenMark Diagnostics to Present at the 2017 J.P. Morgan Healthcare Conference Dec 28 2016
GenMark Diagnostics Submits 510(k) Applications to the FDA for ePlex® Sample-to-Answer Instrument... Dec 22 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)